Evaluation of Safety, Pharmacokinetics, and Efficacy of Proellex Administered Vaginally in Women With Uterine Fibroids
Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
To determine the safety, pharmacokinetics and efficacy of 4 doses (3, 6, 12, 24 mg) of
Proellex in premenopausal women with uterine fibroids confirmed by ultrasound. Drug will be
administered vaginally.